Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Journal of Nanobiotechnology

Fig. 4

From: Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy

Fig. 4

Antitumor efficacy of Co-A15-Exo in vitro. a In vitro viability of MDA-MB-231 cells incubated with control medium (control), Exo, Cho-miR159, Dox, A15-Exo, A15-Exo/Cho-miR159, A15-Exo/Dox, or Co-A15-Exo (2 mM Dox and 500 fmoL/mL Cho-miR159). Cell viability was assessed by performing CCK-8 assays. b Analysis of apoptosis in MDA-MB-231 cells treated by different formulations for 48 h, as determined by flow cytometry after staining for annexin V expression and PI staining. c Relative expression levels of TCF7 mRNA were measured by quantitative real-time PCR after treatment with different formulations in MDA-MB-231 cells. Data are expressed as the mean ± SD (n = 3). d TCF7 and MYC expression were evaluated by western blot analysis

Back to article page